Novo Nordisk to cut US list prices of two insulin products by more than 70%

COPENHAGEN (Reuters) -Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of 2026.

The list prices of its insulin drug Fiasp will be reduced by 75%, while the list prices of its Tresiba insulin will be reduced by 72.2%, Novo said in a statement.

As a result, Novo will discontinue Tresiba’s unbranded biological versions by the end of this year, it added.

(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)